The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
 
Robert M. Jotte
Honoraria - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Federico Cappuzzo
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; pfizer; Roche/Genentech
 
Ihor Vynnychenko
No Relationships to Disclose
 
Daniil Stroyakovskiy
No Relationships to Disclose
 
Delvys Rodriguez Abreu
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Proacta
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Proacta
 
Maen A. Hussein
Stock and Other Ownership Interests - Celgene
Speakers' Bureau - AMAG Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb
 
Ross A. Soo
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Research Funding - AstraZeneca
 
Henry Jacob Conter
Honoraria - Bristol-Myers Squibb; Celgene; Merck; Novartis
Consulting or Advisory Role - Lilly; Roche Canada
 
Toshiyuki Kozuki
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Carlos Silva
No Relationships to Disclose
 
Vilma Graupner
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Shawn Sun
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Ray S Lin
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
 
Claudia Kelsch
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Marcin Kowanetz
Employment - Genentech; Pfizer (I)
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Genentech Mypath
 
Tien Hoang
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Alan Sandler
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Mark A. Socinski
Honoraria - AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech
Consulting or Advisory Role - Genentech
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech
Research Funding - Genentech; Pfizer (Inst)